« Back
Home /
Cabozantinib

Cabozantinib

Manufacturer	MedChem Express
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Breast Cancer Heart & Blood Cancer
Type	Inhibitors
Specific against	other
Clone	N/A
Amount	10mM/1mL
Item no.	HY-13016-10mM
Targets	FLT3, MET, KIT
CASRN	849217-68-1
eClass 6.1	30220300
eClass 9.0	32160605
Available
Product Description	Cabozantinib is a potent and orally active inhibitor of VEGFR2 and MET, with IC50 values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC50=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis[1][2].
StorageTemperature	4°C (Powder, protect from light)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	501.51
Clinical_Information	Launched
Manufacturers Research_Area	Cancer
Solubility	DMSO : 25 mg/mL (ultrasonic)\|H2O : 1 mg/mL (ultrasonic; warming; heat to 60°C)
Isoform	Met; VEGFR1/Flt-1; VEGFR2/KDR/Flk-1; VEGFR3/Flt-4
Pathway	Apoptosis; Protein Tyrosine Kinase/RTK
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-13016-10mM-safety-datasheet.pdf